Pivotal, prospective, Phase III study of Pemetrexed and Pembrolizumab in nonsquamous non small cell lung cancer

Trial Profile

Pivotal, prospective, Phase III study of Pemetrexed and Pembrolizumab in nonsquamous non small cell lung cancer

Planning
Phase of Trial: Phase III

Latest Information Update: 24 Nov 2015

At a glance

  • Drugs Pembrolizumab (Primary) ; Pemetrexed (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 24 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top